Join our daily newsletter At The Bell to receive exclusive market insights
- CSL (CSL) is gearing up to raise capital for the first time in over five years to help it fund an acquisition, as takeover talks with Vifor Pharma continue
- The healthcare giant confirmed recently it was holding talks with Vifor about potentially buying the Swiss-based pharmaceutical company
- CSL entered a trading halt on Tuesday and is due to remain halted until Thursday, unless an announcement can be made sooner
- The ASX-10 lister is interested in Vifor due to its various iron deficiency and iron deficiency anaemia therapies
- CSL shares last traded at $297.27 each on Monday
CSL (CSL) is gearing up to raise capital for the first time in over five years.
The additional funds will help the ASX-10 lister fund an acquisition, as takeover talks with Vifor Pharma continue.
The healthcare giant publicly confirmed it was holding talks about a transaction with Vifor on Monday.
Specifically, CSL is believed to be interested in buying the Swiss-based pharmaceutical company.
The ASX-listed biotechnology business entered a trading halt on Tuesday and is due to remain halted from trade until Thursday.
A full announcement on the capital raise and acquisition is expected to be released on that date unless an announcement can be made sooner.
CSL is interested in a deal with Vifor due to its various iron deficiency and iron deficiency anaemia therapies.
The treatments complement CSL’s own suite of therapies for serious blood diseases, as well as vaccinations — including the AstraZeneca COVID-19 vaccine.
Before today’s trading halt, shares in CSL last traded at $297.27 each on Monday.
